Optison-N 0.1%+0.5% is a Product of the Generic Betamethasone + Neomycin Sulphate (Ophthalmic)

What Is Optison-N 0.1%+0.5% Indications and Uses?

Eye: Inflammatory conditions (eg. uveitis, marginal keratitis, allergic conjunctivitis, blepharitis and episcleritis) where development of bacterial infection is likely.Ear: Otitis externa and other inflammatory conditions where bacterial infection is present or suspected.Nose: Inflammatory conditions where infection is present or suspected.

Pharmacology (Source, Chemical and Physical Composition) Of Optison-N 0.1%+0.5%

Betamethasone is a corticosteroid which is effective in inflammatory dermatoses. It is also effective in less responsive conditions such as psoriasis.  Betamethasone has a 16β-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium and water retaining properties of the fluorine atom bound at carbon 9.Neomycin sulfate is bactericidal against many bacteria which are commonly associated with skin infections. Neomycin is a broad spectrum antibiotic which actively transported across the bacterial cell membrane, binds to a specific receptor protein on the 30s subunit of bacterial ribosomes, and interferes with an initiation complex between mRNA (messenger RNA) and the 30s subunit, inhibiting protein synthesis. DNA may be misread, thus producing nonfunctional proteins; polyribosomes are split apart and are unable to synthesize protein.

Dosage And Administration of Optison-N 0.1%+0.5%

Drop: Eye: 1 or 2 drops to be given into the eye every one or two hours. Ear: 2-3 drops into the ear every two or three hourly. Nose: 2 or 3 drops instilled into each nostril two or three times daily.Ointment: It should be applied thinly and evenly to the conjunctival sac at night (If eye drops used during day) or 3-4 times daily (if ointment used alone).

Side Effects of Optison-N 0.1%+0.5%

Acute sensitization to neomycin is a rare event but can occur after topical application to the eye. Eye drops containing corticosteroids cause a serious rise in intra-ocular pressure in a small percentage of the population, including most of those with a family history of glaucoma. A milder rise may be experienced by a larger proportion of subjects if treatment is continued for longer than a few weeks. Thinning of the cornea leading to perforation has occurred with use of topical corticosteroids. Cataract is reported to have occurred after unduly prolonged treatment of eye conditions with topical corticosteroids.

Use During Pregnancy and Lactation

Pregnancy Category-Not Classified. FDA has not yet classified the drug into a specified pregnancy category. Topical administration of corticosteroid to pregnant animals can cause abnormalities of fetal development. The relevance of this finding to human beings has not been established; however, topical steroids should not be used extensively in pregnancy, i.e. in large amounts or for prolonged periods.

Precautions And Warnings for Optison-N 0.1%+0.5%

Topical steroid should not be used extensively in pregnancy i.e. in large amounts or for prolonged time. Again due to steroid, the preparation should not be administered to red eyes until a definitive diagnosis has been made.

Therapeutic Class

Ophthalmic steroid - antibiotic combined preparations

Storage Conditions of It

Store below 25° C